New York State Common Retirement Fund Has $35.77 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Share on StockTwits

New York State Common Retirement Fund reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 2.7% during the fourth quarter, HoldingsChannel reports. The firm owned 257,083 shares of the biotechnology company’s stock after selling 7,200 shares during the quarter. New York State Common Retirement Fund’s holdings in Ascendis Pharma A/S were worth $35,765,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of ASND. Victory Capital Management Inc. raised its holdings in Ascendis Pharma A/S by 25.0% in the 4th quarter. Victory Capital Management Inc. now owns 547,995 shares of the biotechnology company’s stock valued at $74,034,000 after buying an additional 109,481 shares during the last quarter. California Public Employees Retirement System raised its holdings in Ascendis Pharma A/S by 24.8% in the 4th quarter. California Public Employees Retirement System now owns 53,800 shares of the biotechnology company’s stock valued at $7,485,000 after buying an additional 10,700 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in Ascendis Pharma A/S by 1,076.9% in the 3rd quarter. Voloridge Investment Management LLC now owns 24,361 shares of the biotechnology company’s stock valued at $2,346,000 after buying an additional 22,291 shares during the last quarter. Bank of America Corp DE raised its holdings in Ascendis Pharma A/S by 9.1% in the 2nd quarter. Bank of America Corp DE now owns 22,135 shares of the biotechnology company’s stock valued at $2,549,000 after buying an additional 1,847 shares during the last quarter. Finally, Matisse Capital raised its holdings in Ascendis Pharma A/S by 5.0% in the 3rd quarter. Matisse Capital now owns 10,530 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 500 shares during the last quarter.

Ascendis Pharma A/S stock opened at $141.01 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.75 and a current ratio of 15.74. Ascendis Pharma A/S has a 52-week low of $67.36 and a 52-week high of $145.29. The firm has a 50 day moving average price of $138.30 and a two-hundred day moving average price of $117.11.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Monday, November 18th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.78. Ascendis Pharma A/S had a negative net margin of 789.80% and a negative return on equity of 29.04%. The firm had revenue of $2.49 million during the quarter, compared to analyst estimates of $1.88 million. Equities analysts expect that Ascendis Pharma A/S will post -4.56 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on ASND shares. Wedbush reiterated a “buy” rating and issued a $186.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, November 19th. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Leerink Swann reiterated an “outperform” rating and issued a $152.00 price objective (up previously from $140.00) on shares of Ascendis Pharma A/S in a report on Tuesday, December 3rd. ValuEngine lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Finally, BidaskClub upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $153.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Read More: How prevalent are 12b-1 fees?

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.